Isolation and N-terminal amino acid sequence of an octopamine ligand binding protein  by Nathanson, James A. et al.
Volume 259, number 1, 117-120 FEB 07936 December 1989 
Isolation and N-terminal amino acid sequence of an octopamine ligand 
binding protein 
James A. Nathanson, Lakshmi Kantham and Edward J. Hunnicutt 
Dept. of Neurology, Harvard Medical School and Neuropharmacology Research Laboratory, Massachusetts General Hospital, 
Boston, MA 02114, USA 
Received 18 October 1989 
An octopamine receptor photoaffinity probe was used to label membranes from the light organs of Photinus pyrulis, a tissue highly enriched in 
octopamine receptors. Labeling was concentrated in a glycoprotein of 75 + 2 kDa with lesser labeling of a 79 f 2 kDa component. Labeling could 
be displaced by prior incubation with octopamine, mianserin, cyproheptadine, phentolamine or propranolol, with a relative potency that correlated 
with the ability of these same agents to modulate light organ octopamine-sensitive adenylate cyclase. The 75 kDa binding protein was isolated 
and its N-terminal ammo acid sequence was determined. 
Adrenergic receptor; Adenyl cyclase, octopamine-sensitive; Norsynephrine; Octopamine receptor; (Photinuspyralis) 
1. INTRODUCTION 
OA is a neurotransmitter, neurohormone, and neuro- 
modulator in invertebrates, fulfilling a role analogous 
to that which norepinephrine and epinephrine fulfill in 
vertebrates [l-3]. An OA receptor, coupled to the ac- 
tivation of adenylate cyclase, was first described over 15 
years ago [4], and since then, OA receptor subtypes 
have been defined on the basis of pharmacological 
criteria [5]. However, in contrast to recent advances in 
the isolation of vertebrate amine neurotransmitter 
receptors, little progress has been made in the isolation 
of OA receptor proteins. In part, this has been due to a 
lack of any high-affinity or irreversible OA ligands, a 
problem particularly relevant to isolation of the lower- 
affinity OA receptor(s) coupled to the activation of 
adenylate cyclase. 
bind irreversibly to tissue membranes and such binding 
can be reduced by prior incubation with OA agonists or 
antagonists in a manner indicating that binding is 
occurring at OA receptors [7]. 
We have recently synthesized NC-SZ [6], a com- 
pound which mimics OA’s actions physiologically and 
is 50- to lOGfold more potent than OA in activating 
OA-sensitive adenylate cyclase in a number of in- 
vertebrate tissues [7]. NC-5Z can be photoactivated bo 
Using NC-SZ, we have found that the OA-innervated 
light organs of fireflies are enormously enriched in OA 
receptors [7], containing a density of receptors 
(33-200 nmol/g protein), comparable to that found for 
cholinergic receptors in the electric organ of Torpedo 
[8], where nicotinic receptors constitute 5% of mem- 
brane protein. The high density of OA receptors in the 
light organ is consistent with the very high specific ac- 
tivity of OA-activated adenylate cyclase in the firefly 
tissue (l-4 nmol/mg protein per min), which is among 
the greatest reported for any excitable tissue in the 
aminal kingdom. In this paper, using NC-5Z and mem- 
branes from the light organ, we describe the isolation 
and N-terminal amino acid sequence of an NC-5Z bind- 
ing protein which may represent an OA receptor. 
2. MATERIALS AND METHODS 
2.1. Tissue preparation 
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The nucleotide sequence(s) presented here has (have) been submitted 
to the EMBL/GenBank database under the accession umber Y07523 
Light organs from the firefly, Photinus pyralis, were prepared as 
described [7] and homogenized in 6 mM Tris-maleate buffer, pH 7.4. 
For receptor isolation studies, one-fifth volume of 3 M NaCl was add- 
ed, and tissue was incubated at 25°C for 5 min. The salted 
homogenate was diluted with 30 ml 6 mM Tris-maleate (pH 7.4), cen- 
trifuged at 120000 x g for 30 min, the pellet rehomogenized in 30 ml 
of buffer, and recentrifuged. The final pellet (Pz fraction) was resus- 
pended in a volume of 6 mM Tris-maleate, pH 7.4 (containing 10 mM 
glutathione and 0.1% BSA) equivalent o the starting amount used 
for homogenization and maintained at 0°C until use. For adenylate 
cyclase measurements, the initial tissue concentration was 5 mg wet 
weight/ml and for receptor labeling experiments, 20-50 mg/ml. 
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2.2. Adenylate cyclase assay 
Adenylate cyclase activity was measured, as described in detail in 
[7], in tubes containing (in 0.3 ml) 80 mM Tris-maleate, pH 7.4; 
10 mM theophylline; 8 mM MgClz; 0.1 mM GTP; 0.5 mM EGTA; 
2 mM ATP; 0.06 ml of PZ fraction; and the compounds to be tested. 
For antagonist studies, various concentrations of antagonist were 
tested against a fixed concentration (10 PM) of OA. Inhibitory con- 
stants (K,) for antagonists were calculated as described previously [7]. 
2.3. Photoaffinity labeling 
For affinity labeling, membranes were added to tubes containing 
the reaction mixture described above for the adenylate cyclase assay. 
Displacing agents were added as described in section 3 and the mixture 
was incubated in dim light at 4°C for 15 min, following which 
[3H]NC-5Z (17.4 or 34.4 Ci/mmol) [6] was added to a final concen- 
tration of 0.5 to 3 pM and tubes were incubated for an additional 
30-60 min in the cold. New ATP and GTP was then added and the 
contents of the tubes were transferred to quartz (far UV) minicuvettes 
(1 mm path length, total volume 0.30 ml). Photolysis was carried out 
at 4°C for 15 min at a distance of 3 cm from three 15 W Sylvania 
GTE germicidal lamps (015T8). Cuvettes were turned over every 
2 min during the exposure and following photolysis, the contents 
were transferred to tubes containing 10 ml of 6 mM Tris-maleate, pH 
7.4. Tubes were spun at 120000 x g for 30 min, the pellet resuspended 
in 10 ml of buffer, and washed twice more. The final pellet was 
solubilized (2O~g original wet weight of lantern/pi) in 63 mM Tris 
(pH 6.8) containing 2% SDS and 10% (v/v) glycerol, and placed in 
a boiling water bath for 2 min. After a 15-h incubation at 25”C, the 
protein content was determined, and l/20 volume each of ,& 
mercaptoethanol and 0.1% Bromophenol blue was added to the 
solubilized protein. In some cases, prior to electrophoresis, olubiliz- 
ed proteins were deglycosylated with N-glycanase @enzyme) 
(10 U/ml) for 15 h at 37°C in the presence of 10 mM l,lO-phen- 
anthrolin hydrate to inhibit proteolysis. 
2.4. Electrophoresis 
Aliquots (75-100 pg) of the solubilized proteins were subjected to 
SDS-PAGE [9], using a 12% separating el and a 4% stacking gel and 
running at constant current for 6 h. For greater esolution and for 
blotting, 9% gels were electrophoresed until 30 kDa proteins were run 
off the gel. Gels were stained with 0.05010 Coomassie brilliant blue R, 
then destained, soaked in 2.5% glycerol for 1 h, then in Enlightening 
(DuPont) containing 1% glycerol for 30 min, rinsed briefly in dH20, 
and photographed. Dried gels were mounted on X-ray film for fluo- 
rography at -90°C. [‘H]NC-SZ-labeled protein bands on the 
developed autoradiograms were quantitated using a Helena Labs 
Quick Scan. Labeled peaks were cut out and area was determined by 
weight. For pharmacological studies of displacement of [“HINC-52 
from the receptor protein, the area of an [3H]NC-5Z-labeled peak run 
in the presence of a displacing agent was expressed as a percentage of 
control ([‘HINC-5Z alone) area. 
2.5. Amino acid sequencing 
Western blots were made from gels run as above except hat a 1.5% 
agarose stacking gel was used and the separating el was prerun for 
12 h in Laemmli running buffer containing 0.1 mM thioglycolic acid. 
Gels were blotted onto polyvinylidine difluoride (Immobilon, 
Millipore) membranes in a Hoefer TE-42 transfer apparatus run at 
constant voltage (7 V/cm) for 1 h using a transfer buffer containing 
25 mM Tris, pH 8.3, 192 mM glycine, and 10% methanol. Some 
membranes were incubated with Con A (2.3 /rg/ml) and Con A bind- 
ing was visualized with a biotinylated anti-Con A antibody using 
avidin/biotin peroxidase staining (Vector Labs) with appropriate con- 
trols. The remaining membranes were stained with 0.2% Coumassie 
blue, and areas of membranes containing identified proteins were cut 
out and subjected to N-terminal amino acid sequencing at the Har- 
vard Biology Dept. Microchemical Core Facility using an Applied 
Biosystems Model 470A Gas-phase Sequencer. Phenylthiohydantoin 
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amino acid fractions were identified on-line with an ABI 120A HPLC 
using a C-18 column. Sequencing of the A2 protein was carried out 
twice. 
3. RESULTS AND DISCUSSION 
Fluorographs of [3H]NC-5Z-labeled light organ 
membranes demonstrated two labeled bands: a promi- 
nent band (A2) which corresponded to a protein of M, 
75 + 2 kDa (mean f SD, n =14 experiments), and a 
faint band (Al) which corresponded to a protein of M, 
79 + 2 kDa (n = 13 experiments) (fig.1). Labeling of 
both proteins was displacable when prior to photolysis, 
light organ membranes were incubated with [3H]NC-5Z 
together with OA or with mianserin, a potent OA recep- 
tor antagonist (fig.1). [3H]NC-5Z binding to mem- 
branes was not decreased by norepinephrine, 
dopamine, serotonin or histamine (see [7]). 
To quantitate the pharmacological characteristics of 
binding to A2 and Al, a series of displacement ex- 
periments was carried out with various concentrations 
of OA and several antagonists known to block the light 
organ OA receptor with differing degrees of potency. 
Densitometric scans of A2 labeling on fluorograms 
were integrated and are shown in fig.2A,B. (The phar- 
macology of binding to the Al protein was qualitatively 
similar but, because of its fainter labeling, quantitation 
was not possible.) In other experiments, the drugs used 
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‘Fig. 1. Labeling by [‘H]NC-SZ of firefly light organ membrane pro- 
teins separated by SDS-PAGE on either a 12% gel (A) or a 9% gel (B). 
Protein staining (1); fluorogram of [‘H]NC-5Z labeling showing two 
bands, Al (top arrow) and A2 (bottom) (2,4); displacement of label 
with 1 mM OA (3) or 1 mM mianserin (5). Molecular mass markers 
(kDa) are shown on either side. 
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Fig.2. Displacement of [3H]NC-5Z binding from A2 protein by pre- 
incubation with increasing concentrations of OA (A) or (in B) by an- 
tagonists, mianserin (MIAN), cyproheptadine (CYPRO), phentol- 
amine (PHENT), and propranolol (PROP). The ICSO values (in PM) 
for displacing A2 binding by these agents are plotted in (C) versus the 
K. or Ki values for the same agents in activating or inhibiting light 
organ OA-sensitive adenylate cyclase. 
for displacement were evaluated for their effects on 
light organ OA receptors coupled to adenylate cyclase. 
The Ka value for activation of adenylate cyclase by OA 
and the Kr values for inhibition of OA activation by the 
various antagonists are shown in fig.2C. These values 
are plotted against the I& values (determined from 
fig.2A,B) for the same compounds in displacing label- 
ing of A2. The two sets of values are highly correlated 
(r = 0.986; PC O.Ol), indicating that the pharmacology 
of [3H]NC-5Z binding to the A2 protein is consistent 
with the properties of light organ OA receptors coupled 
to adenylate cyclase activation. Furthermore, as with 
the known very large enrichment of OA receptors in 
light organs, both Al and A2 were visualized by protein 
staining in light organ membranes but could not be seen 
in membranes from firefly head, thorax or abdomen 
(minus light organ). 
Because neurotransmitter receptor proteins are usual- 
ly N-glycosylated at one or more asparagine residues 
[lOI> we subjected light organ membranes to 
deglycosylation with N-glycanase. Of all the light organ 
proteins visualized by Coomassie staining on SDS- 
PAGE, only the Al and A2 proteins showed a shift in 
molecular mass, with a single new band appearing at an 
apparent molecular mass of 72-74 kDa (fig.3). This fin- 
ding, along with the fact that on Western blots, both 
proteins labeled heavily with Con A (data not shown) 
indicates that Al and A2 are glycoproteins. 
Membranes derived from light organs of fireflies 
which had been frozen for various periods of time 
showed a decrease in protein staining of Al and A2 and 
an increased prominence of a band (B) of A4, 
73 + 2 kDa (n = 8 experiments) (fig.4A). In addition, 
incubation of intact, fresh light organs with either OA 
or cholera toxin (which raise cyclic AMP levels in light 
organs [7,1 l]), or with a lipid-soluble CAMP derivative, 
markedly increased staining of a protein located in the 
position of B (fig.4B). In still other experiments (not 
shown), when both Al and A2 were electroeluted from 
gels, concentrated, and then reelectrophoresed, a new 
band appeared at the position of B (along with the 
purified Al and A2 bands). These results suggest hat 
-4*L 
Fig.3. Al and A2 protein bands (left) are shifted to a new band of 
lower molecular mass following deglycosylation with N-glycanase 
(right). 
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Fig.4. (A)Protein staining of Al, A2, and B bands in fresh (1) and 
frozen (2) light organs. (B) Change in pattern of Coomassie staining 
of Al, A2, and B seen following 45 min incubation of fresh, intact 
light organs (3) with 0.3 mM pchlorophenylthio cyclic AMP (4), 
0.4 fig cholera toxin (5), or 1 mM OA (6). 
under some conditions, A2 and/or Al may partially 
break down to a protein of Mr similar to that of B. Al- 
though we observed [3H]NC-5Z labeling of B itself in 
one experiment, this was not a consistent finding; thus, 
whether B represents or is derived from an OA ligand 
binding protein is not clear. 
On Western blots, A2 was obtained in sufficient 
quantity to allow amino acid sequencing. The N- 
terminal was found to be unblocked, and the sequence 
obtained (fig.5) did not match any existing proteins in 
the NBRF protein data base. Although it facilitated se- 
quencing, the observed abundance of A2 (3.7 f 1.4% 
of salt-extracted membrane protein (mean +- SD, 
n = 7)) exceeded the figure (1.5% of membrane protein) 
which would have been expected given the molecular 
mass of A2 and the previously estimated number (up to 
200 nmol/g protein) [7] of Gs-linked OA receptors in 
the light organ. Assuming that there are no spare recep- 
tors undetected by binding studies, this discrepancy 
NH2-Asp-[Asp]-Ile-Lys-Leu-Ser-Gln-Gln-[Tyr]-Asp- 
Val-Leu-Asp-Leu-Phe-Lys-Tyr-Met-[His]-GIn- 
Fig.5. N-terminal amino acid sequence of A2. Amino acids in 
brackets indicate a probable but not definitive sequence. 
raises a question about the possible relationship of A2 
to the Gs-linked OA receptor. On the other hand, sup- 
porting a possible relationship are the glycoprotein 
nature of A2, its pharmacology of binding, its marked 
enrichment in the light organ versus other firefly 
tissues, and the known specificity of NC-SZ for OA 
receptors [7]. Hopefully, use of the data in fig.5 in 
future cloning studies should help to resolve A2’s rela- 
tionship to OA receptors. 
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